Literature DB >> 34811641

18F-FDG-PET glucose hypometabolism pattern in patients with epileptogenic hypothalamic hamartoma.

Chao Lu1,2, Kailiang Wang1,2, Fei Meng1,2, Yihe Wang1,2, Yongzhi Shan3,4, Penghu Wei5,6, Guoguang Zhao7,8,9.   

Abstract

Epileptogenic hypothalamic hamartoma is characterized by intractable gelastic seizures. A systematic analysis of the overall brain metabolic pattern in patients with hypothalamic hamartoma (HH) could facilitate the understanding of the epileptic brain network and the associated brain damage effects of HH. In this study, we retrospectively evaluated 27 patients with epileptogenic HH (8 female patients; age, 2-33 years) by using 18F-fluorodeoxyglucose-positron emission tomography. The correlations among tomography result, seizure type, sex, and structural magnetic resonance imaging were assessed. Whole metabolic patterns and voxel-based morphometry findings were assessed by group analysis with healthy controls. Assessment of the whole metabolic pattern in patients with HH revealed several regional metabolic reductions in the cerebrum and an overall metabolic reduction in the cerebellum. In addition, areas showing hypometabolism in the neocortex were more widely distributed ipsilaterally than contralaterally to the HH. Reductions in glucose metabolism and gray matter volume in the neocortex were predominant ipsilateral to the HH. In conclusion, the glucose hypometabolism pattern in patients with epileptogenic HH involved the neocortex, subcortical regions, and cerebellum. The characteristics of glucose hypometabolism differed across seizure type and sex. Reductions in glucose metabolism and structural changes may be based on different mechanisms, but both are likely to occur ipsilateral to the HH in the neocortex. We hypothesized that the dentato-rubro-thalamic tract and cerebro-ponto-cerebellar tract, which are responsible for intercommunication between the cerebral cortex, subcortical regions, and cerebellar regions, may be involved in a pathway related to seizure propagation, particularly gelastic seizures, in patients with HH.
© 2021. Higher Education Press.

Entities:  

Keywords:  fluorodeoxyglucose-positron emission tomography; gelastic seizure; hypothalamic hamartoma; voxel-based morphometry

Mesh:

Substances:

Year:  2021        PMID: 34811641     DOI: 10.1007/s11684-021-0874-1

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  3 in total

1.  Positron emission tomography in epileptogenic hypothalamic hamartomas.

Authors:  Philippe Ryvlin; C Ravier; S Bouvard; Franois Mauguire; D Le Bars; Alexis Arzimanoglou; Jérôme Petit; Philippe Kahane
Journal:  Epileptic Disord       Date:  2003-12       Impact factor: 1.819

2.  From hypothalamic hamartoma to cortex: what can be learnt from depth recordings and stimulation?

Authors:  Philippe Kahane; Philippe Ryvlin; Dominique Hoffmann; Lorella Minotti; Alim Louis Benabid
Journal:  Epileptic Disord       Date:  2003-12       Impact factor: 1.819

Review 3.  The Significance of the Default Mode Network (DMN) in Neurological and Neuropsychiatric Disorders: A Review.

Authors:  Akansha Mohan; Aaron J Roberto; Abhishek Mohan; Aileen Lorenzo; Kathryn Jones; Martin J Carney; Luis Liogier-Weyback; Soonjo Hwang; Kyle A B Lapidus
Journal:  Yale J Biol Med       Date:  2016-03-24
  3 in total
  2 in total

Review 1.  The heart and gut relationship: a systematic review of the evaluation of the microbiome and trimethylamine-N-oxide (TMAO) in heart failure.

Authors:  Kelley M Anderson; Erin P Ferranti; Emily Couvillon Alagha; Emma Mykityshyn; Casey E French; Carolyn Miller Reilly
Journal:  Heart Fail Rev       Date:  2022-06-21       Impact factor: 4.654

2.  Patterns of hypometabolism in frontal lobe epilepsy originating in different frontal regions.

Authors:  Zexian Zhao; Hong Li; Shan Wang; Cong Chen; Chenmin He; Lingli Hu; Zhe Zheng; Junming Zhu; Meiping Ding; Shuang Wang; Yao Ding
Journal:  Ann Clin Transl Neurol       Date:  2022-07-14       Impact factor: 5.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.